|
|
|
|
Max Planck Institute of Psychiatry, Clinical Institute, 80804 Munich, Germany (C.B., F.L., A.P., M.W., C.J.N., F.H.), and Institute of Anatomy, Charité Berlin, 10098 Berlin, Germany (T.S.)
| |
Summary |
|---|
|
|
|---|
Oxidative stress-induced neuronal cell death has been implicated in
different neurological disorders and neurodegenerative diseases; one
such ailment is Alzheimer's disease. Using the Alzheimer's disease-associated amyloid
protein, glutamate, hydrogen peroxide, and buthionine sulfoximine, we investigated the neuroprotective potential of estrogen against oxidative stress-induced cell death. We
show that 17-
-estradiol, its nonestrogenic stereoisomer,
17-
-estradiol, and some estradiol derivatives can prevent
intracellular peroxide accumulation and, ultimately, the degeneration
of primary neurons, clonal hippocampal cells, and cells in organotypic
hippocampal slices. The neuroprotective antioxidant activity of
estrogens is dependent on the presence of the hydroxyl group in the C3
position on the A ring of the steroid molecule but is independent of an activation of estrogen receptors.
| |
Introduction |
|---|
|
|
|---|
Ovarian steroids are of prime importance in the normal maintenance of brain function; the loss of these steroids at menopause may account, at least in part, for the cognitive decline and neurodegeneration that are associated with AD (1). Consistent with this are the results of population-based studies, which suggest that the increased incidence of AD in older women may be caused by the deficit of the female sex hormone estrogen after menopause and that the use of estrogen during the postmenopausal period can delay the onset and lower the risk of AD (2). Estrogen acts on a number of different target organs, including the brain, that express specific estrogen receptors, and it is a key modulator of processes involved in differentiation, homeostasis, and development of the female reproductive function (3, 4). In addition to a genomic mode of action via transcriptional activation, estrogen and other steroids, such as progesterone derivatives, have been found to produce short term nongenomic actions. These include the modulation of the electrical properties of neurons and of transmitter release processes (5). The nongenomic antioxidant activity of estrogens has received increasing attention recently (6). Oxidative stress and free radical-mediated cell death have been linked to diseases such as atherosclerosis (7) and to a number of neurodegenerative disorders such as Parkinson's disease and AD (8-11).
Because it has been suggested that estrogens, in contrast to all other
natural steroids, are antioxidants of membrane phospholipid peroxidation in cell free systems because of their phenolic structure (6), and because initial data indicate a neuroprotective effect of
17-
-estradiol in vitro (12, 13), we investigated the
neuroprotective potential of estrogen and some of its derivatives
against oxidative stress-induced neurodegeneration. Oxidative damage
and lipid peroxidation can be caused by the neurotoxic amyloid
protein (11) that accumulates in plaques in the brains of AD patients
(14) or by excitatory amino acids such as glutamate, which has also
been implicated in various neurodegenerative diseases (15), via a glutamate receptor-dependent (16) or a glutamate receptor-independent pathway (17, 18). The latter can be mediated through the induction of
an imbalance in antioxidant enzyme systems followed by a reduction in
the levels of intracellular antioxidant glutathione in neurons (17,
18). The main goals of this study were 1) to investigate any possible
protective effects of estrogen for neurons and 2) to identify a
possible structure-activity relationship. Therefore, we tested
17-
-estradiol, 17-
-estradiol, estriol, estrone, ethinyl estradiol, mestranol, quinestrol, and the catechol estrogens
2-OH-estradiol and 4-OH-estradiol (Fig. 1) for their
neuroprotective potential against the oxidative stressors A
and
H2O2. The latter is a mediator of A
toxicity
(11) and a precursor of highly oxidizing, tissue-damaging radicals such
as the lipid peroxidizing hydroxyl radical (19). In addition, glutamate
and BSO, which blocks the de novo biosynthesis of
glutathione (19), were used.
|
| |
Experimental Procedures |
|---|
|
|
|---|
Materials, cell lines, and cell culture.
Cells were cultured
in DMEM supplemented with 10% fetal calf serum under standard culture
conditions. Rat primary cultures from E19 embryonic hippocampi and
mouse primary cortical neurons from E19 embryonic cortices were
prepared as previously described (11, 21). Primary cells were cultured
on poly-L-lysine-coated dishes in a 50% DMEM/50% Ham's
F12 medium that contained N2 supplements. Under these minimal culture
conditions, more than 90% of the cells were stained positive for
neuron-specific enolase. Primary neurons were used after 7-10 days
in vitro. Mouse clonal hippocampal HT22 cells were
cultivated in DMEM supplemented with 10% fetal calf serum. All media,
sera, and medium supplements were from GIBCO (Eggenstein, Germany). The
amyloid
protein used (fragment 25-35) was from Bachem/Saxon
(Hannover, Germany). Glutamate, H2O2, and BSO
were from Sigma (Deisenhofen, Germany), as were all other chemicals.
Stock solutions for the toxins were prepared and diluted in
H2O.
Cytotoxicity and viability assays. Cell viability was assessed using a modified MTT assay as previously described (9, 11, 12). Cell lysis induced by different toxins was assessed with the trypan blue exclusion test followed by cell counting (11, 12). In addition, the fluorescing DNA label PI was used to differentiate between dead cells and living cells (12). All toxicity assays were repeated five times in triplicate determinations. For trypan blue and PI stainings, cells were plated in 60-mm dishes, and the different reagents were added. After 24 hr, trypan blue (at a concentration of 0.12%) or PI (at a concentration of 5 µg/ml) was added, and the number of viable cells (trypan blue-excluding or PI-negative) per low magnification field were determined. For statistical comparisons, analysis of variance followed by a Scheffe's post hoc test was used.
Preparation and culture of organotypic hippocampal slices. Organotypic hippocampal slices were prepared and maintained as previously described (24). Briefly, after decapitation, the brains of 5- to 6-day-old male Sprague-Dawley rats were removed and transferred to cold DMEM. Using a tissue chopper, the hippocampus and the entorhinal cortex were cut into 250-µm slices and were placed on a sterile, porous (0.4 µm) membrane (Millicell; Millipore, Eschborn, Germany). The membranes were transferred into a tissue culture plate and covered with culture medium (final volume 1 ml). The culture medium consisted of 50% DMEM, 25% horse serum, 25% Hanks' balanced salts, and 100 units/ml penicillin/100 µg/ml streptomycin. The culture medium was changed routinely three times a week. Slice cultures were used for experiments after 14 days in vitro.
Detection of intracellular H2O2 and related peroxides. The formation of intracellular peroxides was detected by using DCF-DA as previously described (11, 17). DCF-DA is a nonfluorescent compound that, upon entering cells, is de-esterified and then becomes a substrate to oxidation by intracellular H2O2 and related peroxides. Primary cortical neurons or clonal hippocampal HT22 cells were plated, and toxins were added. After 6 hr, 10 µM DCF-DA was added for 1 hr at 37°. Then, the cells were washed with phenol red-free HEPES-buffered DMEM supplemented with 2% fetal calf serum, and the cultures were viewed with a fluorescence microscope using fluorescein optics. Cultures were compared with treatment condition by an observer blinded to the study, and fluorescence was determined qualitatively by counting the cells first under PC and then under fluorescence. For quantification, >200 cells per low magnification field were counted in five separate experiments, fluorescing cells were determined, and results were expressed as the percentage of fluorescent cells.
| |
Results and Discussion |
|---|
|
|
|---|
Rat primary hippocampal neurons and mouse clonal hippocampal HT22
cells pretreated for 20 hr with 10 µM 17-
-estradiol,
estriol, or estrone and with the nonestrogenic stereoisomer
17-
-estradiol, which does not bind to estrogen receptors and is
therefore biologically inactive (20), were protected against a 24-hr
challenge by A
25-35 (2 µM), the toxic
fragment of A
(21) (Fig. 2, A and B). Cells of both
of these hippocampal cell culture systems were also protected against
H2O2 (30 µM or 60 µM) and BSO (500 µM) by these estrogens (Table 1 and data not shown). A significant increase in
cell survival (p < 0.01) could only be
observed at the 10-µM concentration of these estrogens.
Lower concentrations were not effective, as shown in detail for the
survival of HT22 cells that were pretreated with ethinyl estradiol
after a challenge with either BSO, A
25-35, or glutamate
(Fig. 2C)
|
|
17-
-Estradiol, ethinyl estradiol, quinestrol, mestranol, and the
catechol estrogens 2-OH-estradiol and 4-OH-estradiol were tested for
their neuroprotective activity at 1 µM and 10 µM against BSO and H2O2 in mouse
primary cortical neurons and against glutamate and
H2O2 in HT22 cells. Estradiol is rapidly
converted to 2-OH- and 4-OH-estradiol by an NADPH-dependent cytochrome
P450-linked monooxygenase system in vivo (22). All tested
estrogens that carry an OH group at the C3 position on the A ring of
the steroid molecule afforded neuroprotection in these experimental
paradigms at a concentration of 10 µM (Fig.
3; Table 1). Again, steroid concentrations lower than 10 µM did not afford protection, as shown in detail for
ethinyl estradiol (Fig. 2C). Steroid molecules with an ether-modified
OH group at the C3 position (Fig. 1), such as the 17-
-ethinyl
estradiols quinestrol (3-cyclopentyl ether) or mestranol (3-methyl
ether) and testosterone with a keto group at the C3 position, did not
prevent oxidative stress-induced cell death (Fig. 3; Table 1). After
the glutamate challenge, PC microscopy revealed dramatic changes in
cellular morphology, and PI stainings demonstrated cell death of the
clonal hippocampal HT22 cells. Some experimental data argue for a
receptor-independent pathway of neuroprotection by estrogens because 1)
the addition of the estrogens 2 or 20 hr before the toxic challenge did
not influence the protection afforded (data not shown), 2) high
concentrations must be used to achieve a protective effect, 3) the
addition of actinomycin D as the inhibitor of RNA synthesis did not
block the protective effect (data not shown), 4) HT22 cells that lack endogenous estrogen receptors can be protected (12), and 5) 17-
-estradiol, which does not bind to estrogen receptors, is also
neuroprotective.
|
Incubation of primary cortical neurons with A
and BSO, and treatment
of HT22 cells with glutamate induced an intracellular accumulation of
H2O2 and related peroxides (11) that can be detected with DCF stainings after 6 hr. This increase could be blocked
by the preincubation of cells with different estrogens, as shown
qualitatively in Fig. 3 and quantitatively in Table 1. Peroxides are
precursors of the highly reactive, lipid-peroxidizing hydroxyl radical
(19). Estrogens with an intact 3-OH group on the A ring significantly
reduced the percentage of fluorescent cells after the glutamate
challenge (p < 0.05), whereas quinestrol, mestranol, and testosterone were inactive and could not block these
intracellular oxidative events, which is consistent with a lack of
protective activity (Fig. 3; Table 1).
The hippocampus is a major target of neuronal cell death in neurodegenerative disorders such as AD (23). Organotypic hippocampal slice cultures from postnatal rats preserve the intrinsic connections and regional differentiation specific to the hippocampus in vivo and are frequently used for the investigation of neurotoxins (24). These cultures were established and pretreated with the different estrogens for 20 hr, followed by a strong oxidative challenge with 250 µM H2O2 for 24 hr that induced massive neuronal death in the gyrus dentatus region and the cornu ammonis region (Fig. 4A). The different 3-OH-containing estrogens protected the neuronal cells in the hippocampal slice, as exemplified by ethinyl estradiol, whereas its ether-modified derivatives quinestrol, mestranol, and testosterone were not protective (Fig. 4; data not shown).
|
In neuronal systems, estrogens can exert long term trophic actions and
can stimulate the secretase metabolism of the amyloid
precursor
protein via transcriptional activation after the binding of the
estrogen receptor to estrogen-responsive elements on the DNA
(25-27). These genomic actions of estrogen could potentially affect the AD risk. We report that estrogen and estrogen derivatives within the hydroxyl group in the C3 position on the A ring of the
steroid molecule can also act as powerful neuroprotectants in an
estrogen-receptor-independent short term manner because of to their
antioxidative capacity. The concentrations required for a significant
antioxidative neuroprotection in our in vitro system are
higher than the estrogen levels that occur naturally in vivo
but are consistent with those that have been previously shown to have
antioxidant activity in different cellular and cell-free systems (6,
12). Plasma concentrations of 17-
-estradiol are in the nanomolar
range, depending on sex and menopausal status (28). Interestingly,
17-
-estradiol has been shown to be a more potent antioxidant
inhibitor (IC50 = 21 µM) of iron-catalyzed lipid peroxidation in rat brain homogenates than vitamin E
(IC50 = 30 µM) (29); the latter is currently
being tested in a clinical AD trial. Nevertheless, as shown for the
steroid compound RU486 after oral administration, micromolar steroid
concentrations can be attained in vivo (30).
It is of great significance that the neuroprotective effect against
oxidative stressors in the different neuronal in vitro systems is also afforded by the nonestrogenic 17-
-estradiol, a
compound that is biologically inactive with respect to binding to the
estrogen receptor (20). In summary, our results pin down the
neuroprotective activity of estrogens to the presence of the 3-OH group
of the A ring in the steroid molecule and may therefore serve as a
basis for the design and synthesis of other nonestrogenic antioxidants.
One example could be the synthesis of estrogens with bulky alkyl
substituents in both the 2- and 4-position on the A ring that do not
bind to the estrogen receptor but that nevertheless exert an
antioxidant potential (31).
| |
Acknowledgments |
|---|
We thank R. Rupprecht for helpful comments on the manuscript. We are grateful to P. Maher (Scripps Research Institute, LaJolla, CA) for supplying the HT22 cells.
| |
Footnotes |
|---|
Received November 6, 1996; Accepted January 2, 1997
F.L. was supported by a postdoctoral fellowship from Institute National de la Santé et de la Recherche Médicale. This work was supported in part by a grant of the Wilhelm-Woort-Stiftung für Alternsforschung (C.B.).
Send reprint requests to: Christian Behl, Max Planck Institute of Psychiatry, Clinical Institute, 80804 Munich, Germany. E-mail: chris{at}mpipsykl.mpg.de
| |
Abbreviations |
|---|
AD, Alzheimer's disease;
BSO, buthionine
sulfoximine;
DMEM, Dulbecco's modified Eagle's medium;
PI, propidium
iodide;
PC, phase contrast;
DCF, dichlorofluorescein;
DCF-DA, 2
,7
-dichlorofluorescein diacetate;
MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide;
HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid.
| |
References |
|---|
|
|
|---|
| 1. | Simpkins, J. W., M. Singh, and J. Bishop. The potential role for estrogen replacement therapy in the treatment of the cognitive decline and neurodegeneration associated with Alzheimer's disease. Neurobiol. Aging Suppl. 15:195-197 (1994). |
| 2. |
Paganini-Hill, A. and
V. W. Henderson.
Estrogen deficiency and risk of Alzheimer's disease in women.
Am. J. Epidemiol.
140:256-261 (1994) |
| 3. | McEwen, B. S. Non-genomic and genomic effects of steroids on neural activity. Trends Pharmacol. Sci. 12:141-147 (1991)[Medline]. |
| 4. | Clark, J. H. and E. J. Peck. Female sex steroids, receptors and function. Monogr. Endocrinol. 14:4-36 (1979). |
| 5. | Paul, S. M. and R. H. Purdy. Neuroactive steroids. FASEB J. 6:2311-2322 (1992)[Abstract]. |
| 6. | Ravi Subbiah, M. T., B. Kessel, M. Agrawal, R. Rajan, W. Abplanalp, and Z. Rymaszewski. J. Clin. Endocrinol. Metab. 77:1095-1097 (1993)[Abstract]. |
| 7. | Parthasarathy, S., D. Steinberg, and J. L. Witztum. The role of oxidated low-density lipoproteins in the pathogenesis of atherosclerosis. Annu. Rev. Med. 43:219-225 (1992)[Medline]. |
| 8. |
Coyle, J. T. and
P. Puttfarcken.
Oxidative stress, glutamate, and neurodegenerative disorders.
Science (Washington D. C.)
262:689-695 (1993) |
| 9. |
Yan, S. D.,
X. Cheng,
J. Fu,
M. Chen,
H. Zhu,
A. Roher,
T. Slattery,
L. Zhao,
M. Nagashima,
J. Morser,
A. Migheli,
P. Nawroth,
D. Stern, and
A. M. Schmidt.
RAGE and amyloid- peptide neurotoxicity in Alzheimer's disease.
Nature (Lond.)
382:685-691 (1996)[Medline].
|
| 10. |
Miyata, M. and
J. D. Smith.
Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and -amyloid peptides.
Nat. Gen.
14:55-61 (1996)[Medline].
|
| 11. | Behl, C., J. B. Davis, R. Lesley, and D. Schubert. Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 77:817-827 (1994)[Medline]. |
| 12. | Behl, C., M. Widmann, T. Trapp, and F. Holsboer. 17-Beta estradiol protects neurons from oxidative stress-induced cell death in vitro. Biochem. Biophys. Res. Commun. 216:473-482 (1995)[Medline]. |
| 13. |
Goodman, Y.,
A. J. Bruce,
B. Cheng, and
M. Mattson.
Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid -peptide toxicity in hippocampal neurons.
J. Neurochem.
66:1836-1844 (1996)[Medline].
|
| 14. | Glenner, G. G. Alzheimer's disease: its proteins and genes. Cell 52:307-308 (1988)[Medline]. |
| 15. | Choi, D. W. Excitotoxic cell death. J. Neurobiol. 23:1261-1276 (1992)[Medline]. |
| 16. | Lafon-Cazal, M., S. Pietri, M. Culcasi, and J. Bockaert. NMDA-dependent superoxide production and neurotoxicity. Nature (Lond.) 364:535-537 (1993)[Medline]. |
| 17. | Murphy, T. H., M. Miyamoto, A. Sastre, R. L. Schnaar, and J. T. Coyle. Glutamate toxicity in a neural cell line involves inhibition of cystine transport leading to oxidative stress. Neuron 2:1547-1558 (1989)[Medline]. |
| 18. | Davis, J. B. and P. Maher. Protein kinase C activation inhibits glutamate-induced cytotoxicity in a neuronal cell line. Brain Res. 652:169-173 (1994)[Medline]. |
| 19. | Halliwell, B. Protection against tissue damage in vivo by desferrioxamine: what is its mechanism of action? Free Radical Biol. Med. 7:645-651 (1989)[Medline]. |
| 20. | Gorski, J. A hindsight view of early studies on the estrogen receptor: a personal history. Steroids 59:240-243 (1994)[Medline]. |
| 21. |
Yankner, B. A.,
L. K. Duff, and
D. A. Kirschner.
Neurotrophic and neurotoxic effects of myeloid beta protein: reversal by tachykinin neuropeptides.
Science (Washington D. C.)
250:279-282 (1990) |
| 22. | Jellinck, P. H., J. J. Michnovicz, and H. L. Bradlow. Influence of indole-3-carbinol on the hepatic microsomal formation of catechol estrogens. Steroids 56:446-450 (1991)[Medline]. |
| 23. | Braak, H. and E. Braak. Neuropathological staging of Alzheimer-related changes. Acta. Neuropathol. 82:239-259 (1991)[Medline]. |
| 24. | Diekmann, S., R. Nitsch, and T. G. Ohm. The organotypic entorhinal-hippocampal complex slice culture of adolescent rats. A model to study transcellular changes in a circuit particularly vulnerable in neurodegenerative disorders. J. Neural Transm. Suppl. 44:61-71 (1994)[Medline]. |
| 25. | Ferreira, A. and A. Caceres. Estrogen-enhanced neurite growth: evidence for a selective induction of tau and stable microtubules. J. Neurosci. 11:392-402 (1991)[Abstract]. |
| 26. |
Jaffe, A. B.,
C. D. Toran-Allerand,
P. Greengard, and
S. E. Gandy.
Estrogen regulates metabolism of Alzheimer amyloid beta precursor protein.
J. Biol. Chem.
269:13065-13068 (1994) |
| 27. |
Honjo, H.,
K. Tanaka,
T. Kashiwagi,
M. Urabe,
H. Okada,
M. Hayashi, and
K. Hayashi.
Senile dementia Alzheimer's type and estrogen.
Hormone Metab. Res.
27:204-207 (1995)[Medline].
|
| 28. |
Milgrom, E.
Steroid hormones, in Hormones From Molecules to Disease (E.-E. Baulieu and
P. A. Kelly, eds.). Chapman and Hall, New York, 387-437 (1990).
|
| 29. | Hall, E. D., K. E. Pazara, and K. L. Linseman. Sex differences in postischemic neuronal necrosis in gerbils. J. Cereb. Blood Flow Metab. 11:292-298 (1991)[Medline]. |
| 30. | Heikinheimo, O. and R. Kekkonen. Dose-response relationships of RU-486. Ann. Med. 25:71-76 (1993)[Medline]. |
| 31. | Miller, C. P., I. Jirkovsky, D. A. Hayhurst, and S. J. Adelman. In vitro antioxidant effects of estrogens with a hindered 3-OH function on the copper-induced oxidation of low density lipoprotein. Steroids 61:305-308 (1996)[Medline]. |
This article has been cited by other articles:
![]() |
J. A. Lemon, C. D. Rollo, N. M. McFarlane, and D. R. Boreham Radiation-induced apoptosis in mouse lymphocytes is modified by a complex dietary supplement: the effect of genotype and gender Mutagenesis, November 1, 2008; 23(6): 465 - 472. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Flynn, S. D. Dimitrijevich, M. Younes, G. Skliris, L. C. Murphy, and P. R. Cammarata Role of wild-type estrogen receptor-{beta} in mitochondrial cytoprotection of cultured normal male and female human lens epithelial cells Am J Physiol Endocrinol Metab, September 1, 2008; 295(3): E637 - E647. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Razmara, L. Sunday, C. Stirone, X. B. Wang, D. N. Krause, S. P. Duckles, and V. Procaccio Mitochondrial Effects of Estrogen Are Mediated by Estrogen Receptor {alpha} in Brain Endothelial Cells J. Pharmacol. Exp. Ther., June 1, 2008; 325(3): 782 - 790. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Heldring, A. Pike, S. Andersson, J. Matthews, G. Cheng, J. Hartman, M. Tujague, A. Strom, E. Treuter, M. Warner, et al. Estrogen Receptors: How Do They Signal and What Are Their Targets Physiol Rev, July 1, 2007; 87(3): 905 - 931. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Satoh, C. M. Matter, H. Ogita, K. Takeshita, C.-Y. Wang, G. W. Dorn II, and J. K. Liao Inhibition of Apoptosis-Regulated Signaling Kinase-1 and Prevention of Congestive Heart Failure by Estrogen Circulation, June 26, 2007; 115(25): 3197 - 3204. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Numakawa, T. Matsumoto, D. Yokomaku, T. Taguchi, E. Niki, H. Hatanaka, H. Kunugi, and T. Numakawa 17{beta}-Estradiol Protects Cortical Neurons Against Oxidative Stress-Induced Cell Death through Reduction in the Activity of Mitogen-Activated Protein Kinase and in the Accumulation of Intracellular Calcium Endocrinology, February 1, 2007; 148(2): 627 - 637. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Turgeon, M. C. Carr, P. M. Maki, M. E. Mendelsohn, and P. M. Wise Complex Actions of Sex Steroids in Adipose Tissue, the Cardiovascular System, and Brain: Insights from Basic Science and Clinical Studies Endocr. Rev., October 1, 2006; 27(6): 575 - 605. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Wang, J. A. Dykens, E. Perez, R. Liu, S. Yang, D. F. Covey, and J. W. Simpkins Neuroprotective Effects of 17beta-Estradiol and Nonfeminizing Estrogens against H2O2 Toxicity in Human Neuroblastoma SK-N-SH Cells Mol. Pharmacol., July 1, 2006; 70(1): 395 - 404. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. B. J. Morales, K. K. Loo, H.-b. Liu, C. Peterson, S. Tiwari-Woodruff, and R. R. Voskuhl Treatment with an estrogen receptor alpha ligand is neuroprotective in experimental autoimmune encephalomyelitis. J. Neurosci., June 21, 2006; 26(25): 6823 - 6833. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. B. Dubal, S. W. Rau, P. J. Shughrue, H. Zhu, J. Yu, A. B. Cashion, S. Suzuki, L. M. Gerhold, M. B. Bottner, S. B. Dubal, et al. Differential Modulation of Estrogen Receptors (ERs) in Ischemic Brain Injury: A Role for ER{alpha} in Estradiol-Mediated Protection against Delayed Cell Death Endocrinology, June 1, 2006; 147(6): 3076 - 3084. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Merot, F. Ferriere, E. Debroas, G. Flouriot, D. Duval, and C. Saligaut Estrogen receptor alpha mediates neuronal differentiation and neuroprotection in PC12 cells: critical role of the A/B domain of the receptor J. Mol. Endocrinol., October 1, 2005; 35(2): 257 - 267. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M. Dhandapani, F. M. Wade, V. B. Mahesh, and D. W. Brann Astrocyte-Derived Transforming Growth Factor-{beta} Mediates the Neuroprotective Effects of 17{beta}-Estradiol: Involvement of Nonclassical Genomic Signaling Pathways Endocrinology, June 1, 2005; 146(6): 2749 - 2759. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. G. Smith, L. Betancourt, and Y. Sun Molecular Endocrinology and Physiology of the Aging Central Nervous System Endocr. Rev., April 1, 2005; 26(2): 203 - 250. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Karl, M. Potier, I. H. Schulman, A. Rivera, H. Werner, A. Fornoni, and S. J. Elliot Autocrine Activation of the Local Insulin-Like Growth Factor I System Is Up-Regulated by Estrogen Receptor (ER)-Independent Estrogen Actions and Accounts for Decreased ER Expression in Type 2 Diabetic Mesangial Cells Endocrinology, February 1, 2005; 146(2): 889 - 900. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Jung, M. B. Gatch, and J. W. Simpkins Estrogen Neuroprotection Against the Neurotoxic Effects of Ethanol Withdrawal: Potential Mechanisms Experimental Biology and Medicine, January 1, 2005; 230(1): 8 - 22. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Sortino, M. Chisari, S. Merlo, C. Vancheri, M. Caruso, F. Nicoletti, P. L. Canonico, and A. Copani Glia Mediates the Neuroprotective Action of Estradiol on {beta}-Amyloid-Induced Neuronal Death Endocrinology, November 1, 2004; 145(11): 5080 - 5086. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kurata, M. Takebayashi, S. Morinobu, and S. Yamawaki {beta}-Estradiol, Dehydroepiandrosterone, and Dehydroepiandrosterone Sulfate Protect against N-Methyl-D-aspartate-Induced Neurotoxicity in Rat Hippocampal Neurons by Different Mechanisms J. Pharmacol. Exp. Ther., October 1, 2004; 311(1): 237 - 245. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Zitzler, D. Link, R. Schafer, W. Liebetrau, M. Kazinski, A. Bonin-Debs, C. Behl, P. Buckel, and U. Brinkmann High-throughput Functional Genomics Identifies Genes That Ameliorate Toxicity Due to Oxidative Stress in Neuronal HT-22 Cells: GFPT2 Protects Cells Against Peroxide Mol. Cell. Proteomics, August 1, 2004; 3(8): 834 - 840. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. I. Fernando and J. Wimalasena Estradiol Abrogates Apoptosis in Breast Cancer Cells through Inactivation of BAD: Ras-dependent Nongenomic Pathways Requiring Signaling through ERK and Akt Mol. Biol. Cell, July 1, 2004; 15(7): 3266 - 3284. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Zhang, N. Champagne, L. K. Beitel, C. G. Goodyer, M. Trifiro, and A. LeBlanc Estrogen and Androgen Protection of Human Neurons against Intracellular Amyloid {beta}1-42 Toxicity through Heat Shock Protein 70 J. Neurosci., June 9, 2004; 24(23): 5315 - 5321. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. W. Rau, D. B. Dubal, M. Bottner, L. M. Gerhold, and P. M. Wise Estradiol Attenuates Programmed Cell Death after Stroke-Like Injury J. Neurosci., December 10, 2003; 23(36): 11420 - 11426. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Soldan, A. I. A. Retuerto, N. L. Sicotte, and R. R. Voskuhl Immune Modulation in Multiple Sclerosis Patients Treated with the Pregnancy Hormone Estriol J. Immunol., December 1, 2003; 171(11): 6267 - 6274. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. W. Rau, D. B. Dubal, M. Bottner, and P. M. Wise Estradiol Differentially Regulates c-Fos after Focal Cerebral Ischemia J. Neurosci., November 19, 2003; 23(33): 10487 - 10494. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Prokai, K. Prokai-Tatrai, P. Perjesi, A. D. Zharikova, E. J. Perez, R. Liu, and J. W. Simpkins Quinol-based cyclic antioxidant mechanism in estrogen neuroprotection PNAS, September 30, 2003; 100(20): 11741 - 11746. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. R. Bhavnani, M. Berco, and J. Binkley Equine Estrogens Differentially Prevent Neuronal Cell Death Induced by Glutamate Reproductive Sciences, July 1, 2003; 10(5): 302 - 308. [Abstract] [PDF] |
||||
![]() |
L. Zhao, S. Chen, and R. D. Brinton An Estrogen Replacement Therapy Containing Nine Synthetic Plant-Based Conjugated Estrogens Promotes Neuronal Survival Experimental Biology and Medicine, July 1, 2003; 228(7): 823 - 835. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Shumaker, C. Legault, S. R. Rapp, L. Thal, R. B. Wallace, J. K. Ockene, S. L. Hendrix, B. N. Jones III, A. R. Assaf, R. D. Jackson, et al. Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women: The Women's Health Initiative Memory Study: A Randomized Controlled Trial JAMA, May 28, 2003; 289(20): 2651 - 2662. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. Rapp, M. A. Espeland, S. A. Shumaker, V. W. Henderson, R. L. Brunner, J. E. Manson, M. L. S. Gass, M. L. Stefanick, D. S. Lane, J. Hays, et al. Effect of Estrogen Plus Progestin on Global Cognitive Function in Postmenopausal Women: The Women's Health Initiative Memory Study: A Randomized Controlled Trial JAMA, May 28, 2003; 289(20): 2663 - 2672. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Wang, J. W. Simpkins, J. A. Dykens, and P. R. Cammarata Oxidative Damage to Human Lens Epithelial Cells in Culture: Estrogen Protection of Mitochondrial Potential, ATP, and Cell Viability Invest. Ophthalmol. Vis. Sci., May 1, 2003; 44(5): 2067 - 2075. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. W. Cousins, M. E. Marin-Castano, D. G. Espinosa-Heidmann, A. Alexandridou, L. Striker, and S. Elliot Female Gender, Estrogen Loss, and Sub-RPE Deposit Formation in Aged Mice Invest. Ophthalmol. Vis. Sci., March 1, 2003; 44(3): 1221 - 1229. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Thuillier, Y. Wang, and M. Culty Prenatal Exposure to Estrogenic Compounds Alters the Expression Pattern of Platelet-Derived Growth Factor Receptors {alpha} and {beta} in Neonatal Rat Testis: Identification of Gonocytes as Targets of Estrogen Exposure Biol Reprod, March 1, 2003; 68(3): 867 - 880. [Abstract] [Full Text] [PDF] |